Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
Phase 4
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00304226
- Lead Sponsor
- Novartis
- Brief Summary
The population for this current study will include stage 1 and stage 2 hypertensive patients who are newly diagnosed or didn't have treatment during the last 3 months and patients who are currently treated but uncontrolled on present monotherapy.
The purpose of this study is to evaluate the efficacy of a treatment with valsartan versus a treatment with amlodipine in reaching blood pressure control after 14 weeks of treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1288
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Blood pressure less than 140/90 mmHg after 14 weeks
- Secondary Outcome Measures
Name Time Method Blood pressure less than 140/90 mmHg after 4, 8, and 11 weeks Blood pressure less than 140/90 mmHg after 4, 8, 11, and 14 weeks Time when blood pressure reaches less than 140/90 mmHg Change in blood pressure at baseline, week 4, 8, 11, and 14 Adverse events and serious adverse events at each study visit for 14 weeks
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇨🇭Basel, Switzerland
Novartis Pharmaceuticals🇨🇭Basel, Switzerland